ATLANTA (AP) - Eli Lilly and Co. is looking to increase its total sales of the antipsychotic medication lisurin by 20 percent this year and by 30 percent in 2015, the Indianapolis Star reports. Lisurin, the brand-name version of Eli Lilly's drug schizophrenia, is expected to earn more than $100 million in annual sales in 2015. "Lisurin is the most well-known product in the world. We expect the total volume of sales will be the highest we have seen in years," said Andrew B. Smith, Lilly's chairman and chief executive officer.
The Indianapolis Star report also cites a report from a "very small" group of analysts who have seen the company's revenue decline since its January 2007 purchase of Eli Lilly & Co. by Pfizer. The study estimated that Lilly's total sales would be $3.9 billion in 2015. The analysts cited no substantial growth in the company's total sales since its January 2007 acquisition by Pfizer. Lisurin was the third-best seller and the fifth-best-selling product in the country.
Lilly's sales of schizophrenia have fallen to $1.1 billion in the third quarter of this year, according to the company's financial data. In the quarter, sales of schizophrenia drugs totaled $4.3 billion, down from $3.9 billion in the year-ago period. Sales of the top-selling drug for the year were $8.9 billion, down from $8.1 billion in the same period. Sales of the most-selling drug for the year were $5.5 billion, down from $4.7 billion in the same period. Sales of the antipsychotic drug risperidone totaled $2.7 billion in the third quarter of this year, compared to $2.1 billion in the same period of the year-ago period. Sales of generic versions of the top-selling drugs for the year were $1.3 billion in the third quarter of this year.
Lilly expects full sales growth in 2015, but said that its full-year sales growth will be at a slower pace than expected. "The company expects full sales growth in 2015, but we believe this will be at a slower pace than we expect." Smith said Lilly expects full-year sales growth of about $1.5 billion in 2015. Smith, who was the Lilly chairman from July 1, 2009 to July 31, 2012, also reiterated his forecast for full-year sales growth of about $1.3 billion in 2015.
For more information, visit www.lilly.com.
Copyright © 2011 AP or its affiliates All rights reserved.Lilly Pharmaceuticals Inc. and its affiliated subsidiaries are not approved by the U. S. Food and Drug Administration, and no part of the information, content, or materials provided on this site may be used for diagnosing or treating a disease condition, condition, treatment, or disorder; as described in the labeling supplied with the products, or as otherwise permitted by law.
is an educational, research-based, non-profit organization dedicated to providing quality, affordable prescription medications to the most vulnerable in the United States. We believe that by helping our members do better, by encouraging them to take control of their lives, and by providing them access to high-quality health care, this organization will be a lifeline for all of us.
is a non-profit corporation that provides health care assistance to the United States, paying no financial or other aid to individuals with low incomes. The information on this site is for general informational purposes only and is not a substitute for the expertise and judgment of our doctors, nurses, pharmacists, or other qualified healthcare professionals.does not prescribe, accept or use the trade names, or names of any of its approved products, and disclaims any and all implied warranties of accuracy or reliability as to the product names, including that the information on this site is current, and that it may be used for a specific purpose. The information on this site may be used to provide educational and assist-in-tour materials for the members of the public. does not endorse or recommend any of the products, nor does it recommend that they be used for any purpose other than that described in the labeling supplied with the products. The information on this site should not be considered,a copy of the printed or electronic product orany copy of the printed or electronic product as a copy does not constitute a substitute for the expertise and judgment of a doctor or other practitioner.
Strattera (atomoxetine hydrochloride) is a medication used in the treatment of attention-deficit hyperactivity disorder (ADHD) that is available in many countries and has been prescribed for many patients. The active ingredient in Strattera is atomoxetine. It is a selective norepinephrine reuptake inhibitor that works by increasing the levels of norepinephrine in the brain, which in turn increases the activity of dopamine and norepinephrine in the brain. By blocking the reuptake of norepinephrine, Strattera helps to increase the levels of dopamine and norepinephrine in the brain and improves focus and attention span in patients with ADHD.
Strattera is a prescription medication that is used to treat attention-deficit hyperactivity disorder (ADHD), and to treat depression. Strattera belongs to a class of drugs called selective norepinephrine reuptake inhibitors. It works by increasing the levels of norepinephrine, which is a neurotransmitter in the brain. By blocking the reuptake of norepinephrine, Strattera helps to increase the levels of dopamine and norepinephrine in the brain, which in turn improves attention span and reduces hyperactivity. Strattera can also be used as a treatment for ADHD, and it is not considered to be an addictive medication.
Strattera is also used to treat the symptoms of narcolepsy. Strattera works by blocking the reuptake of norepinephrine, which is a neurotransmitter in the brain. This increases the levels of norepinephrine, which in turn improves focus and reduces hyperactivity.
Strattera is available in the form of capsules. The dosage of Strattera is usually determined by the doctor based on the symptoms of the patient and the severity of their symptoms. It is important to follow the doctor's instructions carefully and not exceed the recommended dose.
Strattera is not recommended for use in children under 18 years of age. It is also not recommended for use in patients with liver or kidney impairment.
If Strattera is not suitable for you, the doctor may prescribe a different medication or different dosages. You can take Strattera with or without food. It is advisable to take the dose of Strattera 1 hour before or 2 hours after a meal to prevent a dose of Strattera from forgetting your dose. It is not recommended to take Strattera more than once a day.
Strattera is not effective for treating ADHD. The patient should take Strattera only when they are experiencing symptoms of ADHD. It is not a good idea to take Strattera when you are taking medications such as Strattera to treat depression or anxiety. It is essential to follow the doctor's instructions and not to exceed the recommended dose. Taking Strattera with food can cause an upset stomach and can make Strattera more difficult to take.
The medication should be taken once per day and should not be taken more than once per day. Patients should not take Strattera more than once a day.
To make sure that Strattera is not a good fit for you, tell the doctor if you have a history of heart problems, kidney problems, liver problems, or other medical problems that can make it unsuitable for you. If you are not sure, talk to your doctor.
The most common side effects of Strattera are headache, flushing, nasal congestion, dizziness, and dry mouth. If you experience any side effects after taking Strattera, stop taking it immediately and contact your doctor.
If you are not sure about any side effects, consult your doctor.
In conclusion, Strattera can be a useful treatment for attention-deficit hyperactivity disorder (ADHD) and depression. It is not recommended to take Strattera with or without food. It is essential to consult with your doctor before taking Strattera to ensure that it is safe for you to take.
Patient InformationIf you are interested in learning more about Strattera (atomoxetine hydrochloride), please read our guide. We will be happy to share your experience with your doctor and other medical professionals for a personalized treatment plan.
₦19,700.00Original price was: ₦19,700.00.20,700.00Current price is: ₦20,700.00.
Strattera is a medication used to treat attention deficit hyperactivity disorder (ADHD) in children. It is also used to help children with attention deficit disorder (ADP). Unlike traditional ADHD medications, Strattera works by increasing the levels of certain chemicals in the brain.
Strattera comes in three forms: oral, injection and tablet.
Your doctor may start you at the first form and gradually increase your dose. This helps improve your performance in school and your ability to concentrate in the office environment.
Strattera is a medication that is used to treat ADHD and other.
ADHD is a neurological disorder that affects the ability to pay attention, concentrate and finish tasks. It’s characterized by low or no ability to pay attention or concentrate in the time it takes to complete tasks.
ADHD can be classified as part of a broader disorder called, which means you have two symptoms. The first one is called hyperactivity and impulsiveness. The second symptom is called a lack of focus or behavior changes. Both of these symptoms are also present in the first symptom of ADHD.
Strattera works by increasing the levels of a substance called atomoxetine in your body. It works by increasing the amount of this chemical in your brain. Atomoxetine is a type of medication called a selective norepinephrine reuptake inhibitor. This medication helps treat or prevent the symptoms of ADHD.
Strattera is a prescription medication that is used to treat attention deficit hyperactivity disorder (ADHD).
It is one of the most commonly used medications in the treatment of ADHD. This medication is also used to help children and teens with ADHD to become more focused, organized, and active in school. It works by increasing the levels of norepinephrine and dopamine in the brain. Low or no norepinephrine and high dopamine levels help improve attention, focus, and impulse control.
Strattera is not addictive.
Strattera is usually taken as a single pill. The dose can vary depending on the child and the severity of the condition. The usual starting dose is 1 to 2 milligrams (mg) every 4 to 6 hours. The dosage may be increased to 3 mg once per day for 3 months or increased to 5 mg two to four times per day for 5 years.
The length of treatment depends on your symptoms and the child’s age and severity of the condition. If you are experiencing a condition called attention deficit hyperactivity disorder (ADHD), the dosage may be increased to the maximum recommended dose of 60 mg per day.
Some people taking Strattera may experience mild to moderate side effects such as:
If any of these symptoms do not go away or if these symptoms worsen, consult your doctor immediately.
Taking Strattera with certain medications may interact with Strattera. For example, Strattera may reduce the effectiveness of certain antidepressants.
Medically reviewed by Jessica Swirble, PharmDLast updated on April 18, 2025
Drug Information| | |
Atomoxetine is a medication indicated for the treatment of ADHD in both children and adults. It is also indicated for the treatment of symptoms of ADHD in both children and adults.
atomoxetine hydrochlorideis a prescription medication for the treatment of ADHD. It is indicated for the treatment of attention-deficit hyperactivity disorder (ADHD).
Atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD).
Atomoxetine works by affecting the dopamine and norepinephrine dopamine receptors in the brain.
Atomoxetine is also used to treat symptoms of depression.
Atomoxetine is used to treat symptoms of depression.
Atomoxetine is indicated for the treatment of symptoms of depression.
Prescription only.
The dosage of atomoxetine varies depending on the patient's age and the severity of the condition. Your doctor will determine the appropriate dose for your condition.
The duration of treatment for atomoxetine depends on the specific condition being treated. Follow your doctor's instructions.
The use of atomoxetine can lead to side effects such as dizziness, headache, nausea, dry mouth, and decreased libido. Some individuals may experience sleeping more than recommended, especially during the daytime. Consult your doctor before taking this medication if you are interested in taking atomoxetine?
Last updated on April 18, 2025
Strattera is a prescription medication for the treatment of attention-deficit hyperactivity disorder (ADHD).
Atomoxetine is a medication indicated for the treatment of hyperactivity in adult patients with ADHD. It is also indicated for symptoms of ADHD.
Atomoxetine is a medication indicated for the treatment of hyperactivity in adult patients with attention-deficit hyperactivity disorder (ADHD).
The dosage of atomoxetine depends on the specific condition being treated.
The duration of treatment for atomoxetine depends on the condition being treated.
Stade de France Pharmacy